Search results

Technologies 5

• Soft hydrogel electrodes for better, safer implants
  Soft, conductive hydrogels match the physical properties of the human brain, enabling the creation of electrodes and implantable devices that can improve brain-machine interfaces while reducing the risk of injury.
• CogniXense for Rare Disease Drug Discovery
  Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome.
• CogniXense: A Platform for Rapid Drug Repurposing
  CogniXense is a target-agnostic drug discovery platform that enables the repurposing of drugs for rare genetic diseases in record time. By combining human data-based computational drug prediction with on-demand animal model development, we can mimic the diversity of symptoms of patient populations and begin drug screening on new diseases within a month.
• Soft Robotic Shoulder Support for Stroke Rehabilitation
  The majority of stroke survivors have difficulty using their affected arm in everyday life. Commercial rehabilitation robots exist, but most are expensive, rigid, non-portable exoskeletons that can only be used in clinical rehabilitation settings. Portable devices could considerably increase the frequency and amount of robotic therapy, maximizing the recovery possible for patients with arm impairments....
• Wearable stochastic resonance technology for supporting neurological function
  Accelera has licensed the Wyss Institute’s stochastic resonance technology to develop fully wearable medical devices that support neurological function in patients with cerebral palsy and other conditions.

News 16

View all

• Video/​Animation
  
  The Wyss Brain Targeting Program is expanding its “neural network”
  January 25, 2024
• Press Release
  
  Novel test holds promise for detecting Parkinson’s disease early
  January 10, 2024
• Awards
  
  Wyss Institute’s CircaVent team awarded grant from BD² to advance research into bipolar disorder and development of more effective drugs
  October 3, 2023

Multimedia 4

• 

  Video/Animation
  CogniXense: Speeding Up Treatments for Rare Diseases
  At the Wyss Institute, we are tackling Rett syndrome, a rare disease that affects 1 out of 9,000 children, by developing a scalable model for neurodevelopmental and cognitive diseases. This model can test drugs to see which will improve memory, learning, and behavior, with the end goal of finding effective therapies. Credit: Wyss Institute at...

• 

  Video/Animation
  Multi-joint Personalized Soft Exosuit Breaks New Ground
  A multidisciplinary team at Harvard’s Wyss Institute and Harvard SEAS has developed a mobile multi-joint soft exosuit using an automatic tuning strategy that could reduce fatigue in soldiers, firefighters or other rescue workers. Credit: Wyss Institute at Harvard University

• 

  Video/Animation
  Wyss Study: Memory Genes
  Researchers at the Wyss Institute and the Personal Genome Project (PGP) are using Lumosity games to evaluate memory functions and response times. The genomes of high performers will be sequenced, with the goal of uncovering the relationship between genetics, memory, attention, and reaction speed. This video featuring George Church, Core Faculty of the Wyss Institute and Professor...

• 

  Video/Animation
  Fluorescent in situ Sequencing
  In this video, George Church, Ph.D., a Core Faculty member at the Wyss Institute and Professor of Genetics at Harvard Medical School, explains how fluorescent in situ sequencing could lead to new diagnostics that spot the earliest signs of disease, and how it could help reveal how neurons in the brain connect and function. Credit:...